抄録
In 178 RA patients, I studied the continued use rate and clinical results of bucillamine over a 2-year period. The results indicate that the continued use rate was 69.1% which was more favorable than in the groups treated using GST or auranofin. Most probably the reason for this is that in the long term administration cases there were few ineffective drop-out cases.
Clinical results included a slight or moderate improvement on the final Lansbury improvement rate in more than 68.9% of the cases. On various evaluation items, periodic changes showed improvement up to the 6 th month of administration and these improvements were maintained for up to 2 years.
The continuity of these effects supports the fact that the number of cases who discontinued due to decrease of efficacy was small.
